SI-BONE, Inc. SIBN
Set alert
At close
Pre-market · Nov 3, 4:00 AM ET
- YTD
- +2.54%
- 1 year
- +34.35%
- Open
- 21.57
- Prev close
- 21.23
- Mkt cap
- 906.23M
- Vol
- 1.37M
- Avg vol
- 588.22K
- EPS
- -0.34
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 20.19
- High
- 21.83
- Forward P/E
- -67.74
- Beta
- 0.66
- Short ratio
- 8.24
- Inst. own
- 109.52%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 5, 2024
- 50-d avg
- 19.33
- 200-d avg
- 16.36
- 1y target
- 25.44
5D chart
Signals (108)
| Name | Time | Ago |
|---|---|---|
| SMA: Bullish | Oct 30, 3:55 PM | 3 days ago |
| SMA: Bearish | Oct 30, 3:35 PM | 3 days ago |
| SMA: Bearish | Oct 30, 3:35 PM | 3 days ago |
| SMA: Bullish | Oct 30, 3:10 PM | 3 days ago |
| SMA: Bearish | Oct 30, 3:05 PM | 3 days ago |
| SMA: Bullish | Oct 30, 2:55 PM | 3 days ago |
| RSI: Oversold | Oct 30, 2:20 PM | 3 days ago |
| MACD: Buy Signal | Oct 30, 1:25 PM | 3 days ago |
| SMA: Bullish | Oct 30, 1:15 PM | 3 days ago |
| RSI: Oversold | Oct 30, 12:40 PM | 3 days ago |
| RSI: Oversold | Oct 30, 12:25 PM | 3 days ago |
| SMA: Bearish | Oct 30, 12:10 PM | 3 days ago |
| MACD: Sell Signal | Oct 30, 12:10 PM | 3 days ago |
| RSI: Oversold | Oct 30, 12:10 PM | 3 days ago |
| SMA: Bearish | Oct 30, 11:50 AM | 3 days ago |
| SMA: Bullish | Oct 30, 11:30 AM | 3 days ago |
| MACD: Buy Signal | Oct 30, 10:35 AM | 3 days ago |
| RSI: Oversold | Oct 30, 9:50 AM | 3 days ago |
| RSI: Oversold | Oct 30, 9:30 AM | 3 days ago |
| SMA: Bearish | Oct 29, 3:15 PM | 4 days ago |
Newest 20 of 108.
News
9 hours ago seekingalpha.com
SI-BONE, Inc. (SIBN) Q3 2026 Earnings Call Transcript
SI-BONE, Inc. (SIBN) Q3 2026 Earnings Call Transcript
11 hours ago marketbeat.com
SiBone Q3 Earnings Call Highlights
SiBone NASDAQ: SIBN reported third-quarter 2026 revenue growth of 14.5% as procedure demand accelerated, active physician adoption expanded and profitability improved. The company said it is building…
12 hours ago zacks.com
Si-Bone (SIBN) Reports Q3 Loss, Tops Revenue Estimates
Si-Bone (SIBN) came out with a quarterly loss of $0.08 per share versus the Zacks Consensus Estimate of a loss of $0.13. This compares to a loss of $0.11 per share a year ago.
13 hours ago benzinga.com
SI-BONE Q3 2026 Earnings Call Transcript
SI-BONE (NASDAQ:SIBN) reported third-quarter financial results on Monday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to you by…
-
15 hours ago benzinga.com
SI-BONE Affirms FY2026 Sales Guidance of $231.000M-$233.000M vs $232.024M Est
SI-BONE (NASDAQ:SIBN) affirms FY2026 sales outlook from $231.000 million-$233.000 million to $231.000 million-$233.000 million vs $232.024 million estimate.
-
15 hours ago benzinga.com
SI-BONE Q3 EPS $(0.08) Beats $(0.13) Estimate, Sales $55.704M Beat $55.404M Estimate
SI-BONE (NASDAQ:SIBN) reported quarterly losses of $(0.08) per share which beat the analyst consensus estimate of $(0.13) by 33.33 percent. This is a 27.27 percent increase over losses of $(0.11) per…
15 hours ago globenewswire.com
SI-BONE, Inc. Reports Financial Results for the Third Quarter 2026 and Reaffirms 2026 Revenue Guidance
Delivered ~20 % U.S. procedure volume growth in the third quarter Third Quarter 2026 Financial Highlights (all comparisons are to the prior year period) Worldwide revenue of $55.7 million,…
4 days ago globenewswire.com
SI-BONE To Present at UBS Global Healthcare Conference on November 10, 2026
SAN JOSE, Calif., Oct. 29, 2026 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), the global leader in developing procedural solutions to address clinical challenges associated with compromised bone,…
-
2 weeks ago benzinga.com
Truist Securities Maintains Buy on SI-BONE, Raises Price Target to $25
Truist Securities analyst Richard Newitter maintains SI-BONE (NASDAQ:SIBN) with a Buy and raises the price target from $23 to $25.
-
1 month ago benzinga.com
SI-BONE Receives FDA Clearance For Its iFuse Granite Onyx System
SI-BONE, Inc. (NASDAQ:SIBN), the global leader in developing procedural solutions to address clinical challenges associated with compromised bone, today announced U.S. Food and Drug Administration…
1 month ago benzinga.com
12 Health Care Stocks Moving In Friday's After-Market Session
Gainers Scinai Immunotherapeutics (NASDAQ:SCNI) shares rose 25.3% to $2.08 during Friday's after-market session. The market value of their outstanding shares is at $1.1 million. Corbus Pharmaceuticals
-
3 months ago benzinga.com
Truist Securities Reiterates Buy on SI-BONE, Raises Price Target to $23
Truist Securities analyst Richard Newitter reiterates SI-BONE (NASDAQ:SIBN) with a Buy and raises the price target from $21 to $23.
-
3 months ago benzinga.com
TD Cowen Maintains Buy on SI-BONE, Raises Price Target to $20
TD Cowen analyst Mathew Blackman maintains SI-BONE (NASDAQ:SIBN) with a Buy and raises the price target from $18 to $20.
3 months ago benzinga.com
12 Health Care Stocks Moving In Monday's After-Market Session
Gainers Ensysce Biosciences (NASDAQ:ENSC) stock rose 118.1% to $0.61 during Monday's after-market session. The market value of their outstanding shares is at $3.8 million. TransCode Therapeutics…
-
3 months ago benzinga.com
SI-BONE Raises FY2026 Sales Guidance from $230.000M-$233.000M to $231.000M-$233.000M vs $231.775M Est
SI-BONE (NASDAQ:SIBN) raises FY2026 sales outlook from $230.000 million-$233.000 million to $231.000 million-$233.000 million vs $231.775 million estimate.
-
3 months ago benzinga.com
SI-BONE Q2 EPS $(0.09) Beats $(0.15) Estimate, Sales $56.010M Beat $55.335M Estimate
SI-BONE (NASDAQ:SIBN) reported quarterly losses of $(0.09) per share which beat the analyst consensus estimate of $(0.15) by 40 percent. This is a 35.71 percent increase over losses of $(0.14) per…
-
3 months ago benzinga.com
UBS Initiates Coverage On SI-BONE with Buy Rating, Announces Price Target of $24
UBS analyst Patrick Wood initiates coverage on SI-BONE (NASDAQ:SIBN) with a Buy rating and announces Price Target of $24.
-
3 months ago benzinga.com
Truist Securities Maintains Buy on SI-BONE, Raises Price Target to $21
Truist Securities analyst Richard Newitter maintains SI-BONE (NASDAQ:SIBN) with a Buy and raises the price target from $18 to $21.
5 months ago benzinga.com
Zebra Technologies, Vishay Precision Group, Quantum Computing, Aramark And Other Big Stocks Moving Higher On Tuesday
ZBRA, VSTS, AMBQ, VPG, BAK, PACS, LOT, EIKN, DDD, WEN, SIBN post significant gains on better-than-expected financial results and guidance. Peltz may take Wendy's private.
-
5 months ago benzinga.com
TD Cowen Maintains Buy on SI-BONE, Lowers Price Target to $18
TD Cowen analyst Mathew Blackman maintains SI-BONE (NASDAQ:SIBN) with a Buy and lowers the price target from $22 to $18.
-
5 months ago benzinga.com
Truist Securities Reiterates Buy on SI-BONE, Lowers Price Target to $18
Truist Securities analyst Richard Newitter reiterates SI-BONE (NASDAQ:SIBN) with a Buy and lowers the price target from $20 to $18.
5 months ago benzinga.com
Why Harmonic Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarket
Harmonic Inc (HLIT) rose in pre-market trading after beating earnings expectations & raising guidance. Other gainers include Buzzfeed, MacroGenics, & SI-Bone.
-
5 months ago benzinga.com
SI-BONE Raises FY2026 Sales Guidance from $228.500M-$232.500M to $230.000M-$233.000M vs $230.387M Est
SI-BONE (NASDAQ:SIBN) raises FY2026 sales outlook from $228.500 million-$232.500 million to $230.000 million-$233.000 million vs $230.387 million estimate.
-
5 months ago benzinga.com
SI-BONE Q1 EPS $(0.10) Beats $(0.18) Estimate, Sales $52.588M Beat $51.105M Estimate
SI-BONE (NASDAQ:SIBN) reported quarterly losses of $(0.10) per share which beat the analyst consensus estimate of $(0.18) by 44.44 percent. This is a 33.33 percent increase over losses of $(0.15) per…
-
6 months ago benzinga.com
Truist Securities Maintains Buy on SI-BONE, Lowers Price Target to $20
Truist Securities analyst Samuel Brodovsky maintains SI-BONE (NASDAQ:SIBN) with a Buy and lowers the price target from $24 to $20.
-
8 months ago benzinga.com
TD Cowen Maintains Buy on SI-BONE, Raises Price Target to $22
TD Cowen analyst Mathew Blackman maintains SI-BONE (NASDAQ:SIBN) with a Buy and raises the price target from $21 to $22.
-
8 months ago benzinga.com
Truist Securities Reiterates Buy on SI-BONE, Raises Price Target to $24
Truist Securities analyst Richard Newitter reiterates SI-BONE (NASDAQ:SIBN) with a Buy and raises the price target from $23 to $24.
-
8 months ago benzinga.com
SI-BONE Q4 EPS $(0.04) Beats $(0.12) Estimate, Sales $56.350M Beat $55.397M Estimate
SI-BONE (NASDAQ:SIBN) reported quarterly losses of $(0.04) per share which beat the analyst consensus estimate of $(0.12) by 67.48 percent. This is a 63.64 percent increase over losses of $(0.11) per…
-
8 months ago benzinga.com
Earnings Scheduled For February 23, 2026
Earnings Scheduled For February 23, 2026
8 months ago benzinga.com
A Look Ahead: SI-BONE's Earnings Forecast
A Look Ahead: SI-BONE's Earnings Forecast
-
9 months ago benzinga.com
A Glimpse Into The Expert Outlook On SI-BONE Through 5 Analysts
A Glimpse Into The Expert Outlook On SI-BONE Through 5 Analysts
-
9 months ago benzinga.com
TD Cowen Initiates Coverage On SI-BONE with Buy Rating, Announces Price Target of $21
TD Cowen analyst Mathew Blackman initiates coverage on SI-BONE (NASDAQ:SIBN) with a Buy rating and announces Price Target of $21.
-
9 months ago benzinga.com
SI-BONE Reports Preliminary Q4 Global Revenue Between $56.2M - $56.3M, 2025 Global Revenue Between $200.8M - $200.9M
SI-BONE, Inc. (Nasdaq: SIBN), the global leader in developing procedural solutions to address clinical challenges associated with compromised bone, today announced its preliminary and unaudited…
10 months ago benzinga.com
Why Did SI-Bone (SIBN) Surge Spike After Hours?
SI-Bone shares rose in after-hours trading as three executives sold stock last week to cover RSU tax obligations.
-
10 months ago benzinga.com
Truist Securities Maintains Buy on SI-BONE, Raises Price Target to $23
Truist Securities analyst David Rescott maintains SI-BONE (NASDAQ:SIBN) with a Buy and raises the price target from $21 to $23.
-
10 months ago benzinga.com
Canaccord Genuity Maintains Buy on SI-BONE, Raises Price Target to $27
Canaccord Genuity analyst Caitlin Roberts maintains SI-BONE (NASDAQ:SIBN) with a Buy and raises the price target from $26 to $27.
10 months ago benzinga.com
Accenture To Rally More Than 16%? Here Are 10 Top Analyst Forecasts For Tuesday
Accenture To Rally More Than 16%? Here Are 10 Top Analyst Forecasts For Tuesday
-
10 months ago benzinga.com
Needham Maintains Buy on SI-BONE, Raises Price Target to $27
Needham analyst David Saxon maintains SI-BONE (NASDAQ:SIBN) with a Buy and raises the price target from $24 to $27.
-
11 months ago benzinga.com
Morgan Stanley Maintains Overweight on SI-BONE, Raises Price Target to $23
Morgan Stanley analyst Drew Ranieri maintains SI-BONE (NASDAQ:SIBN) with a Overweight and raises the price target from $20 to $23.
11 months ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Intraday Session
12 Health Care Stocks Moving In Tuesday's Intraday Session
-
11 months ago benzinga.com
SI-BONE Raises FY2025 Sales Guidance from $195.000M-$198.000M to $198.000M-$200.000M vs $196.584M Est
SI-BONE (NASDAQ:SIBN) raises FY2025 sales outlook from $195.000 million-$198.000 million to $198.000 million-$200.000 million vs $196.584 million estimate.
-
11 months ago benzinga.com
SI-BONE Q3 EPS $(0.11) Beats $(0.17) Estimate, Sales $48.656M Beat $46.667M Estimate
SI-BONE (NASDAQ:SIBN) reported quarterly losses of $(0.11) per share which beat the analyst consensus estimate of $(0.17) by 36.05 percent. This is a 31.25 percent increase over losses of $(0.16) per…
11 months ago benzinga.com
Earnings Scheduled For November 10, 2025
Earnings Scheduled For November 10, 2025
-
1 year ago benzinga.com
Truist Securities Maintains Buy on SI-BONE, Lowers Price Target to $20
Truist Securities analyst David Rescott maintains SI-BONE (NASDAQ:SIBN) with a Buy and lowers the price target from $22 to $20.
-
1 year ago benzinga.com
Cantor Fitzgerald Reiterates Overweight on SI-BONE, Maintains $25 Price Target
Cantor Fitzgerald analyst Ross Osborn reiterates SI-BONE (NASDAQ:SIBN) with a Overweight and maintains $25 price target.
-
1 year ago benzinga.com
SI-BONE Raises FY2025 Sales Guidance from $193.500M-$197.500M to $195.000M-$198.000M vs $195.834M Est
SI-BONE (NASDAQ:SIBN) raises FY2025 sales outlook from $193.500 million-$197.500 million to $195.000 million-$198.000 million vs $195.834 million estimate.
-
1 year ago benzinga.com
SI-BONE Q2 EPS $(0.14) Beats $(0.19) Estimate, Sales $48.630M Beat $48.112M Estimate
SI-BONE (NASDAQ:SIBN) reported quarterly losses of $(0.14) per share which beat the analyst consensus estimate of $(0.19) by 24.73 percent. This is a 36.36 percent increase over losses of $(0.22) per…